Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder

Zhichao Li, Lin Wan, Xinting Liu, Jing Wang, Xiu‐Yu Shi, Huanfen Zhou, Quangang Xu, Shihui Wei, Guang YangFrontiers in Immunology 2023 · DOI

This study, published in Frontiers in Immunology, investigates the use of plasma exchange (PE) as a "salvage" therapy for children suffering from Neuromyelitis Optica Spectrum Disorder (NMOSD) who do not respond to standard steroid treatments. By analyzing six pediatric cases, the researchers highlight a critical "golden window" for treatment: starting PE early (within 10 days of an attack) may be the difference between permanent disability and clinical recovery.

TL;DR

Plasma exchange can be a life-changing rescue therapy for pediatric NMOSD, but its success is highly time-dependent. In this small case series, only the patient treated within 10 days of symptom onset showed significant improvement, while those treated later saw no benefit and faced risks like thrombosis and thrombocytopenia.

What Problem Does This Paper Address?

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare but devastating autoimmune disease where the body attacks the central nervous system, specifically targeting the optic nerves and spinal cord. In children, the AQP4-IgG positive subtype is particularly aggressive, often leading to rapid blindness or paralysis.

While high-dose steroids are the first line of defense, many patients are "corticosteroid-unresponsive." For these children, plasma exchange (PE)—a process that filters the blood to remove pathogenic antibodies—is used as a last resort. However, because the disease is so rare in children, there is very little data on when PE should be started and how safe it is for smaller bodies. This paper seeks to fill that gap by documenting real-world clinical outcomes and adverse events.

Methods

The researchers conducted a retrospective case series of six pediatric patients (all female, aged 4 to 13) treated at a single center in China between 2015 and 2022.

  • The Procedure: Patients underwent standard PE using a COM.TEC Cell Separator. The protocol typically involved five cycles performed every other day.
  • The "Washout": Plasma was removed and replaced with 5% albumin, sometimes supplemented with fresh frozen plasma (FFP).
  • Evaluation: Clinical progress was measured using visual acuity (VA) tests and the Expanded Disability Status Scale (EDSS), which quantifies neurological impairment.

Datasets

The study relies on a small, specialized clinical dataset of six pediatric patients from the First Medical Center of Chinese PLA General Hospital. All patients were confirmed AQP4-IgG positive and had previously failed to respond to intravenous methylprednisolone (IVMP).

Key Insights and Ideas

  • The Criticality of Timing: The median delay between symptom onset and PE initiation was 29 days. The only patient who recovered significantly (Patient 3) started PE just 10 days after her exacerbation. This suggests that once the inflammatory damage to the optic nerve or spinal cord is "set," removing the antibodies may be too late to reverse the deficit.
  • Safety Concerns in Small Patients: PE is technically challenging in children due to smaller blood volumes and difficult vascular access. Half of the patients in this study experienced adverse events, ranging from minor rashes to a serious non-occlusive thrombosis in the jugular vein.
  • The "Salvage" Paradox: Because PE is often reserved as a "rescue" therapy after steroids fail, it is frequently initiated late by default. The authors argue for a shift in thinking: if a child shows severe neurological deficits, waiting weeks to see if steroids work might cost them their sight or mobility.

Key Results

  • Clinical Success: Only 1 out of 6 patients showed improvement. Patient 3’s visual acuity improved from 0.06 to 0.6, and her EDSS score dropped from 4 to 3.
  • Treatment Failure: The other 5 patients saw no clinical improvement and no change in their EDSS scores, likely due to the long delay (up to 98 days) before starting PE.
  • Adverse Events:
    • Rashes: 2 patients.
  • Thrombocytopenia (low platelet count): 1 patient (treatment had to be stopped after 2 cycles).
  • Thrombosis: 1 patient developed acute non-occlusive thrombosis of the internal jugular vein.

Limitations and Future Work

The primary limitation is the very small sample size (n=6) and the retrospective nature of the study, which relies on existing medical records. Additionally, most patients in this study were not experiencing their first attack, which may have limited their recovery potential.

The authors conclude that while PE is a viable rescue therapy, it carries significant risks that must be weighed against potential benefits. They call for larger, prospective multicenter studies to establish a definitive "cutoff" time for PE initiation in pediatric NMOSD to maximize the chances of recovery.

Summary updated

Abstract

Neuromyelitis optica spectrum disorder (NMOSD), a severe demyelinating disease, is rare among children. Plasma exchange (PE) is widely used as a salvage therapy for severe and corticosteroid-unresponsive patients with NMOSD. Presently, there are limited studies on the safety and efficacy of PE in children with NMOSD. Herein, we report the case of six children with NMOSD who received PE along with the outcomes and adverse events. All six children (female, age at onset 4 years 9 months-13 years 2 months) were AQP4-IgG positive and received standard PE using the COM.TEC Cell Separator. The interval between NMOSD onset and PE was 29 days (range 10-98). Only one patient (P3) who received PE 10 days after acute exacerbations exhibited clinical improvement. Her left visual acuity increased from 0.06 to 0.6 (spectacle-corrected visual acuity was 1.0) and her EDSS score decreased from 4 to 3 points. The other five patients had no clinical improvement and no EDSS scores changes after PE. Adverse events included rashes (P1, P3), acute non-occlusive thrombosis of the internal jugular vein (P1), and thrombocytopenia (P2). In conclusion, the timing of PE initiation as a rescue therapy for severe and corticosteroid-unresponsive pediatric AQP4-IgG positive NMOSD may be crucial to treatment efficacy, and early initiation of PE may be associated with a better outcome. Furthermore, PE has the potential risk for clinically significant adverse effects that should be considered before initiating the therapy and should be weighed against potential benefits.
BibTeX
@inproceedings{li2023safety,
  author = {Zhichao Li and Lin Wan and Xinting Liu and Jing Wang and Xiu‐Yu Shi and Huanfen Zhou and Quangang Xu and Shihui Wei and Guang Yang},
  title = {{Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2022.1113406},
}
Figure